Physician profile
Olga Lansky
NPI 1326019407
$4,015.60
in general payments reported to CMS, 2019-2025
35 companies · $36.69 in 2025
The $36.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,896 · 2020: $758 · 2021: $643 · 2022: $454 · 2023: $72.30 · 2024: $156 · 2025: $36.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.49 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $471.90 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $434.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $434.15 | 2019-2022 | |
| Pfizer INC. | $420.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $171.95 | 2019-2022 | |
| Allergan, INC. | $162.05 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $137.39 | 2024 | Austedo Xr |
| Astellas Pharma US INC | $109.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $93.83 | 2019-2021 | |
| Abbott Laboratories | $93.06 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $58.79 | 2019 | |
| Lilly USA, LLC | $55.38 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $53.44 | 2022-2023 | Ingrezza |
| Ferring Pharmaceuticals INC. | $45.11 | 2019-2020 | |
| Novo Nordisk INC | $44.68 | 2021-2022 | |
| Vivus LLC | $44.63 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $40.42 | 2019-2020 | |
| Amarin Pharma, INC. | $38.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.23 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $36.67 | 2019-2020 | |
| Ibsa Pharma INC. | $35.49 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.07 | 2019 | |
| Nestle Healthcare Nutrition INC. | $32.52 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.16 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.66 | 2022 | |
| Dexcom, INC. | $19.51 | 2020 | |
| Clarus Therapeutics INC. | $17.93 | 2021 | |
| Depuy Synthes Sales INC. | $16.55 | 2019 | |
| Bioventus LLC | $16.09 | 2019 | |
| Lundbeck LLC | $14.20 | 2023 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $13.19 | 2022 | |
| Eisai INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Lansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.